Cordis Bilateral AAA Device Compared to Open Surgical Repair of Abdominal Aortic Aneurysms (ARIBA)

This study has been completed.
Sponsor:
Information provided by:
Cordis Corporation
ClinicalTrials.gov Identifier:
NCT00235118
First received: October 6, 2005
Last updated: December 8, 2005
Last verified: October 2005
  Purpose

The objective of this study is to assess the safety and effectiveness of the Cordis Bilateral AAA device and its Delivery System compared to open surgical repair for the treatment of Abdominal Aortic Aneurysm (AAA).


Condition Intervention Phase
Abdominal Aortic Aneurysm
Device: Cordis AAA Bilateral Device
Phase 1
Phase 2

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: An Evaluation of the Safety and Effectiveness of the Cordis Bilateral AAA Device Compared to Open Surgical Repair for the Treatment of Abdominal Aortic Aneurysm

Resource links provided by NLM:


Further study details as provided by Cordis Corporation:

Primary Outcome Measures:
  • Primary success is defined as freedom from all of the following: rupture of aneurysm, enlargement of aneurysm > 0.5 cm on CT scan, with or without endoleak, as compared to any previous measurement, symptomatic aneurysm requiring treatment.
  • The absence of major complications at thirty days defined as arterial thrombosis, respiratory impairment, renal failure, myocardial infarction (M.I.) and stroke in combination with the absence of major complications at one year.

Secondary Outcome Measures:
  • · Technical success defined as the successful access and deployment of the device at the appropriate anatomic location with aneurysmal exclusion determined by angiography at the time of deployment.
  • ·

Estimated Enrollment: 29
Study Start Date: December 1999
Estimated Study Completion Date: February 2006
  Eligibility

Ages Eligible for Study:   40 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

- Anatomic (stent-graft)

Aortic Aneurysm Diameter

  • > 4.5 cm
  • Those aortic aneurysms < 4.5 cm that are at least 1.5 times the diameter of the aorta with a size increase of 5 mm or greater over a six month period will also be included for possible treatment.
  • Aorto-iliac aneurysms in which the aortic aneurysm is < 4.5 cm but the iliac artery aneurysms are > 3.0 cm in diameter or there is evidence of recent expansion (5 mm or greater over a six month period) in iliac aneurysms < 3.0 cm.
  • Saccular aortic aneurysms > 3.0 cm.

Aortic Neck

  • Diameter > 17 mm and < 28 mm (Phase I)
  • Diameter > 14 mm and < 28 mm (Phase II)

Angulation Neck Length < 45° > 15 mm <60° > 25 mm

Iliac Arteries

  • Diameter > 8 mm and < 18 mm (Phase I and Phase II)
  • At least one common iliac artery with a cuff > 15 mm.

Diameter Aortic Neck Common Iliac 26-28 mm 13–18 mm 23-25.9 mm 10-17 mm 20-22.9 mm 9–15 mm 17-19.9 mm 8-13 mm 14-16.9 mm 8-11mm

*NOTE: An aortic diameter cannot be treated if the iliac diameter is not in the same range (e.g. 26-28 mm aortic necks must be in conjunction with 13-18 mm common iliacs).

Anatomic (surgical controls)

· Surgical controls will be required to meet only the aortic or aorto-iliac aneurysm size requirements for anatomic inclusion criteria.

Aortic Aneurysm Diameter

  • > 4.5 cm
  • Those aortic aneurysms <4.5 cm that are at least 1.5 times the diameter of the aorta with a size increase of 5 mm or greater over a six month period will also be included for possible treatment.
  • Aorto-iliac aneurysm in which the aortic aneurysm is <4.5 cm but the iliac artery aneurysm are >3.0 cm in diameter or there is evidence of recent expansion (5 mm or greater over a six month period) in iliac aneurysms <3.0 cm.
  • Saccular aortic aneurysms > 3.0 cm.
  • Clinical (stent-graft)
  • Males and non-pregnant females > 40 years of age.
  • Clinical (surgical controls)

Surgical control patients will be required to meet all of the above-stated stent-graft clinical inclusion criteria.

Exclusion Criteria:

Anatomic (stent-graft)

Aortic Aneurysm Diameter

· < 4.5 cm that are not at least 1.5 times the diameter of the aorta with evidence of a size increase of 5 mm or greater within a six month period.

Aorto-iliac Aneurysms

  • < 3.0 cm in diameter unless evidence of recent expansion (5 mm or greater within a six month period).
  • The iliac portion of the aneurysm extending to the bifurcation bilaterally which would necessitate covering both internal iliac arteries with the device.

Aortic Neck

  • Diameter < 17 mm and > 28 mm (Phase I)
  • Diameter < 14 and >28 (Phase II)
  • Thrombus lined
  • Highly calcified

    • NOTE: See inclusion criteria for length below the renals and degree of angulation.

Iliac Arteries

  • < 8 mm and > 18 mm (native) (Phase I and Phase II)
  • Highly calcified (common)
  • Neither common iliac artery with a cuff > 15 mm.

    • NOTE: See inclusion criteria for aortic neck and iliac artery diameters.

Anatomic (surgical controls)

· Surgical controls will be excluded based only on the aortic or aorto-iliac aneurysm size requirements for anatomic exclusion criteria.

Aortic Aneurysm Diameter

· < 4.5 cm that are not at least 1.5 times the diameter of the aorta with evidence of a size increase of 5 mm or greater within a six month period.

Aorto-Iliac Aneurysms

  • < 3.0 cm in diameter unless evidence of recent expansion (5 mm or greater within a six month period).
  • The iliac portion of the aneurysm extending to the bifurcation bilaterally which would necessitate surgically covering both internal iliac arteries.

Clinical (stent-graft)

  1. Ruptured abdominal aortic aneurysm.
  2. Renal insufficiency – creatinine level > 2.5 mg/dl.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00235118

Locations
United States, New York
Mt. Sinai Hospital
New York, New York, United States, 10029
Sponsors and Collaborators
Cordis Corporation
Investigators
Principal Investigator: Michael Marin, MD Mt. Sinai Hospital
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00235118     History of Changes
Other Study ID Numbers: P98-4601
Study First Received: October 6, 2005
Last Updated: December 8, 2005
Health Authority: United States: Food and Drug Administration

Additional relevant MeSH terms:
Aneurysm
Aortic Aneurysm
Aortic Aneurysm, Abdominal
Vascular Diseases
Cardiovascular Diseases
Aortic Diseases

ClinicalTrials.gov processed this record on July 24, 2014